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Objectives: Patients receiving induction therapy may have increased risk of mor-
bidity and mortality after surgery. We retrospectively evaluated the influence of
preoperative treatment in patients who underwent sleeve resection for lung cancer.
Methods: A series of 48 consecutive patients who underwent sleeve resection with
a telescoping anastomosis was retrospectively analyzed. A sleeve lobectomy and
pneumonectomy were performed in 41 and 7 patients, respectively. Twenty patients
received preoperative induction therapy; of them, 16 received induction chemora-
diotherapy and 4 received only chemotherapy. Twenty-eight patients underwent the
procedure without adjuvant therapy.
Results: The telescopic procedure was performed by placing sutures around the
proximal and distal portions of the bronchial cartilage without wrapping the anas-
tomosis. Among the 20 patients who received induction therapy, pulmonary angio-
plasty was performed in 5 and chest wall resection was performed in 3. Seven of
these 20 patients (35%) had postoperative complications. Among the 28 patients
without preoperative adjuvant therapy, pulmonary angioplasty was performed in 3,
diaphragmatic resection was performed in 1, and chest wall resection was performed
in 1. Three of these 28 patients (11%) had postoperative complications. Complica-
tions relating to the anastomosis occurred in 1 patient (5.0%) who received induc-
tion therapy; however, no operative deaths occurred. Bronchoscopic examinations
demonstrated that mucosal healing was prolonged in patients who underwent
induction therapy.
Conclusion: Induction therapy did not significantly affect morbidity or mortality
among patients who underwent sleeve resection.
Preoperative induction chemoradiotherapy is considered to improvesurvival; however, the treatment may also induce related complica-tions.1-3 Various techniques involving vital tissues have been used tolessen the usually high incidence of postoperative complicationsamong patients undergoing bronchial sleeve resection after inductiontherapy.4-6 We have had some success with a telescoping anastomosis
for primary sleeve resection without any anastomosis-related complications, so in
1993 we also began to use a telescoping method for bronchoplasty procedures after
induction therapy. A recent study found that preoperative chemotherapy did not
significantly affect morbidity or mortality after surgery,7 and our experience with
sleeve resections after induction therapy confirmed those results. We examined the
influence of induction therapy on sleeve resection surgical results by retrospectively
comparing patients who received induction therapy with those who did not.
Patients and Methods
We treated 484 patients with lung cancer from 1993 to 2001, of whom 48 (9.9%) underwent
circumferential resection of the bronchus or carina with pulmonary resection. Forty-one of
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those patients underwent sleeve lobectomy and 7 underwent sleeve
pneumonectomy (Table 1). There were 35 male and 13 female
patients ranging in age from 38 to 84 years (mean 59 years).
Histologic examinations revealed squamous cell carcinoma in 30
patients, adenocarcinoma in 13, adenosquamous cell carcinoma in
1, typical carcinoid in 3, and adenoid cystic carcinoma in 1. In each
case we elected to perform a telescoping anastomosis for sleeve
resection. The preoperative conditions, findings, and results from
these patients were examined in a retrospective analysis.
Evaluation of Stage and Treatment Strategy
The patients routinely underwent computed tomographic exami-
nation of the chest and upper abdomen, magnetic resonance im-
aging of the head, bone scans, lung function tests, and fiberoptic
bronchoscopy. In those with insufficient lung function, lung per-
fusion scans were also performed. Patients with stages IIIA and
IIIB disease received induction therapies before the operation.
Mediastinal lymphadenopathy was diagnosed by chest computed
tomography without histologic confirmation, whereas supraclavic-
ular lymphadenopathy and malignant pleural effusion were diag-
nosed by pathologic examination. Patients with malignant pleural
effusion, contralateral mediastinal lymphadenopathy, or pulmo-
nary metastasis were excluded. However, 1 patient who had a
right-sided Pancoast tumor with ipsilateral supraclavicular lymph
node metastasis (N3 disease) was included. Before induction ther-
apy, there were 14 patients with N2 disease, 1 with N3 disease, 9
with T3 disease, and 7 with T4 disease; thus 12 patients had stage
IIIA disease and 8 had stage IIIB disease.
Sixteen patients received cisplatin-based combination chemo-
therapy with concurrent radiation therapy to the primary tumor and
mediastinum before the operation, and another 4 patients received
only chemotherapy. Chemotherapy treatments consisted of four
different combinations: cisplatin and vindesine were administered
to 11 patients; cisplatin, vindesine, and mitomycin were adminis-
tered to 4 patients; cisplatin and docetaxel were administered to 4
patients; and low-dose carboplatin as an enhancer of radiation was
administered to 1 patient. All patients, except for 2 in the cisplatin
and vindesine therapy group, received two cycles of chemother-
apy. Radiation therapy with an average of 42 Gy (range 30-50 Gy)
was initiated concurrently at 2 Gy/(fraction  d) on the first day of
the initial cycle of chemotherapy. Patients receiving induction
therapy underwent surgical resection of the residual tumor at the
primary site and vestiges on neighboring organs within 4 weeks
after the last treatment.
Sleeve lobectomy was achieved with an anteroaxillar thoracot-
omy in principle. When a radical pretracheal or paratracheal
lymphadenectomy was required in a left-sided operation, a trap-
door thoracotomy (half median sternotomy with fourth intercostal
space thoracotomy) was performed. A standard posterolateral tho-
racotomy was used for right sleeve pneumonectomy and a bilateral
anteroaxillar thoracotomy was performed for left sleeve pneumo-
nectomy to achieve adequate dissection of the mediastinal lymph
nodes.
Operative Procedure
Resection of the subcarinal, paratracheal, and hilar peribronchial
lymph nodes was carried out before bronchial incision. For pa-
tients with a Pancoast tumor, a supraclavicular lymphadenectomy
was also performed. The anastomosis was constructed of a single
interrupted whole-layer suture with 4-0 PDS-II or Maxon sutures
for sleeve lobectomy and 3-0 PDS-II (Ethicon, Inc, Somerville,
NJ) or Maxon (United States Surgical Corp, Norwalk, Conn)
TABLE 1. Patient characteristics
Surgery after
induction therapy
Surgery
alone P value
No. of patients 20 28
Age (y, mean  SD) 58 10 62 10 .18
Sex (male/female ratio) 14:6 21:7 .95
Histologic type (No.)
Squamous cell carcinoma 13 17
Adenocarcinoma 7 6
Other 0 5 .11
Clinical stage before treatment (No.)
I 0 6
II 0 15
IIIA 12 2
IIIB 8 5 .0001
Type of operation (No.)
Sleeve pneumonectomy 3 4
Sleeve lobectomy 16 18
Sleeve bilobectomy 1 6 .28
Combined operation
() 12 24
Angioplasty of pulmonary artery,
pulmonary vein, or superior
vena cava
5 3
Chest wall resection 3 1 .12
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sutures for sleeve pneumonectomy. After two sutures were placed
around the cartilages at the mediastinal end, the first suture was
tied in an extraluminal fashion. The subsequent suture was then
placed before the second suture was knotted (Figure 1). The
telescoping effect was achieved by placing the stitches around the
proximal and distal cartilage. The anastomosis of the membranous
portion was performed with either an interrupted or a continuous
suture technique. When the anastomosis was complete, the bron-
chus was telescoped by a depth of one circumference of cartilage.
Wrapping of the anastomosis was not performed; however, a
pedicled pericardial fat pad was used for coverage of the vascular
anastomosis in cases of combined vascular sleeve resection. The
anastomosis was checked for leaks with a pressure of 30 cm H2O
for 3 seconds.
Types of Operations
Twenty patients received preoperative induction therapy, of whom
17 underwent sleeve lobectomy and 3 underwent sleeve pneumo-
nectomy (2 right and 1 left). Five of these 20 patients underwent
lobar pulmonary angioplasty and 3 underwent chest wall resection.
In addition, 28 patients underwent primary sleeve resection with-
out adjuvant therapy, of whom 24 underwent sleeve lobectomy and
4 underwent right-sided sleeve pneumonectomy. Two of these
patients underwent angioplasty of a pulmonary artery or vein, 1
underwent resection of the diaphragm, and 1 underwent angio-
plasty and chest wall resection.
Fiberoptic Bronchoscopic Examinations after Surgery
At the end of the operation, the anastomosis was inspected with a
bronchoscope. Bronchoscopic examination was repeated 1 and 2
weeks later, or every week if postoperative complications or pro-
longed mucosal healing at the anastomotic site was observed.
Statistical Analysis
Differences between two groups were tested for significance by the
2 test for categoric variables and the Student t test for continuous
variables. Survival was estimated by the Kaplan-Meier method.
Results
Clinical factors of the patients who underwent sleeve resec-
tion after induction therapy were similar to those of patients
without induction therapy except for clinical stage (Table
1).
Complications in Patients Who Received Induction
Therapy
A total of 7 patients who received induction therapy (35%)
had postoperative complications (Table 2). Two patients
with poor pulmonary function required mechanical ventila-
tion with tracheotomy, and 1 patient acquired pneumonitis
from methicillin-resistant Staphylococcus aureus and re-
ceived medical treatment under mechanical ventilation. Fur-
ther complications included 1 patient who underwent dis-
section of a right-sided Pancoast tumor and had recurrent
nerve and ulnar nerve palsy develop, 2 patients who had
pleural empyema develop, and 1 patient in whom stricture
of the anastomosis, which developed after infection with
Pseudomonas cepacia at the anastomosis site, was success-
fully treated with balloon dilatation after the infection had
resolved. Bronchoscopic examination frequently revealed
white, necrotic mucosa along the cartilage of the distal
bronchial end, which persisted for approximately 3 weeks.
Complications in Patients Without Induction Therapy
Three patients who did not receive induction therapy (11%)
had postoperative complications develop (Table 2). One
patient required mechanical ventilation for 2 days after
surgery because of laryngeal edema, 1 acquired pleural
empyema, and 1 acquired chylothorax.
The rates of morbidity were 35% (n  7/20) among
patients who received induction therapy and 11% (n 
3/28) among those who did not. An anastomosis-related
Figure 1. Telescoping bronchial anastomosis procedure. Anastomosis is initiated from mediastinal side of cartilage
with 4-0 PDS-II sutures. Placement of sutures around cartilage is critical in achieving good telescoping effect.
Cartilage sutures are tied and membranous portion is sutured. Distal bronchus is then inserted into proximal
bronchus at depth equal to circumference of cartilage.
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complication was observed in 1 patient who received induc-
tion chemoradiotherapy. No postoperative deaths occurred,
and all patients were discharged in an ambulatory condition.
Survival and Cause of Death
Patients were followed up from 4 to 93 months (mean SD
25.4 19.6 months). For the analysis of survival, 3 patients
with carcinoid lung cancer and 1 with adenoid-cystic car-
cinoma were excluded, because the prognoses for these
types of lung cancer are much better than for other types of
non-small cell lung cancer. Four patients who received
induction therapy died between postoperative months 16
and 53. One of these had local recurrence in the mediasti-
num 13 months after the operation, 2 had tumor recurrence
at a distant site, and 1 died of a non-tumor-related cause. Six
who did not receive induction therapy died between post-
operative months 5 and 32. One of these patients had local
recurrence in the residual lung 30 months after surgery, 5
had tumor recurrence at a distant site, and 1 died of pneu-
monitis. The median survivals were 19.3 months for all 44
patients, 23 months for the 20 patients who received induc-
tion therapy, and 17.9 months for the 24 who did not receive
induction therapy.
Discussion
Chemotherapy or chemoradiotherapy followed by surgery is
considered to be an effective treatment modality for locally
advanced lung cancer in stage IIIA or IIIB. However, lung
resections after induction therapy are technically demand-
ing, and between 27% and 56% of the patients with an
infiltrative centrally located tumor require pneumonecto-
my.5,8 Rendina and colleagues4 showed that a bronchoplasty
with vascular reconstruction could reduce the rate of pneu-
monectomy to 7.3% and considered bronchovascular recon-
structive surgery to be an effective alternative to a pneumo-
nectomy after induction chemotherapy. In our series of
patients, induction therapy was indicated for those with
stages IIIA and IIIB disease. When the patients had a
resectable T4 tumor, such as a carinal invasion without N2
or N3 disease, a primary operation was performed. Overall,
we performed surgery on 86 patients after induction ther-
apy, 20 (23%) of whom underwent sleeve resection. The
choice of sleeve resection for patients after induction ther-
apy was based on curative intent and the desire to preserve
as much functional lung volume as possible. The 28 patients
who did not receive induction therapy underwent operations
with the same intent.
Induction therapy, particularly irradiation, may cause
serious anastomotic complications.9,10 According to several
reports, radiotherapy before sleeve resection should be
avoided9,11 or limited to 30 Gy.12 When sufficient irradia-
tion dosages are used, the use of omentum to enhance the
blood supply is recommended.6 When preoperative chemo-
therapy is performed, bronchial sutures should be protected
by well-vascularized tissue, such as an intercostal muscle
flap.4 In the patients in this retrospective study, wrapping to
prevent early complications may have been unnecessary, as
shown in a previous experimental report,13 even for patients
who received induction therapy. Moreover, a telescopic
procedure without wrapping has frequently been applied to
single-lung transplantation with good results.14 We believe
that for a successful telescope it is crucial to achieve a depth
equal to one cartilage and to cover the full circumference of
the bronchus. A telescoping anastomosis seems to be a
simple and reliable technique, especially for patients receiv-
ing induction therapy.
The results from our series of 48 consecutive cases
indicate that bronchoplasty can be performed fairly safely in
patients undergoing induction therapy, including irradiation.
Morbidity of patients undergoing airway reconstruction
with wrapping of a vascularized tissue flap after induction
chemotherapy has been reported to be 11% (n 3/27),4 and
the rate increased to 36% (n 8/22) when concomitant with
radiotherapy.6 Our postoperative morbidity rate of 35%
among patients who received induction therapy lies within
that range, and the rate of anastomotic stricture was only
5.0% (n  1/20). Further, the morbidity rate among the 28
patients who underwent a sleeve resection without induction
therapy was 11%, and no anastomosis-related complications
were observed in that group.
TABLE 2. Postoperative results
Surgery after
induction therapy
Surgery
alone P value
No. of patients 20 28
Complications (No.)
Reintubation or
tracheotomy for
respiratory failure
2 1
Pneumonia 1 0
Empyema 2 1
Stricture of anastomosis 1 0
Other 1 1
Total 7 3 .092
Pathologic stage* (No.) .2
I 5 7
II 2 9
IIIA 9 6
IIIB 4 6
Survival† n 20 n 24
Median survival (mo) 23 17.9 .58
Death from cancer (No.) 3 5
Death other than from
cancer (No.)
1 1 .97
*Pathologic stage was based on pathologic examinations of resected
specimen and operative findings.
†Median survival was calculated for all patients without carcinoid and
adenocystic carcinoma.
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Our patients had no local recurrences in the airway;
however, 2 (4.2%) had intrathoracic relapses of disease and
7 had relapses at a distant site. The median survival was 23
months among patients with induction therapy and 18
months among those without it. Although it is not appro-
priate to compare median survivals between the patients
who received induction therapy and those who did not
because they had different stages of disease, the median
survival findings for our patients who received induction
therapy compared favorably with those in other major se-
ries.2,5,8 Our study population was not large enough to
detect small differences in surgical morbidity or survival, so
the influence of induction therapy must be carefully evalu-
ated. Nevertheless, the surgical outcomes relating to bron-
chial anastomosis were similar to the best results reported
elsewhere.4,12
In summary, the results of our retrospective study sug-
gest that morbidity and mortality after sleeve resection were
not significantly affected by preoperative induction therapy
when a meticulous technique was used and proper patient
selection was performed.
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